tiprankstipranks
Aligos Therapeutics (DE:5WK0)
FRANKFURT:5WK0
Germany Market

Aligos Therapeutics (5WK0) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

5WK0 Analyst Ratings

Strong Buy
4Ratings
Strong Buy
4 Buy
0 Hold
0 Sell
Based on 4 analysts giving stock ratings to
Aligos
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

5WK0 Stock 12 Month Forecast

Average Price Target

€62.59
▲(1688.20% Upside)
Based on 4 Wall Street analysts offering 12 month price targets for Aligos Therapeutics in the last 3 months. The average price target is €62.59 with a high forecast of €151.07 and a low forecast of €17.27. The average price target represents a 1688.20% change from the last price of €3.50.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","77":"€77","152":"€152","39.5":"€39.5","114.5":"€114.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":151.0722675,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€151.07</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":62.58708225,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€62.59</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.265402,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€17.27</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,39.5,77,114.5,152],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.705,15.040943653846155,26.376887307692307,37.71283096153846,49.048774615384616,60.384718269230774,71.72066192307692,83.05660557692308,94.39254923076923,105.72849288461539,117.06443653846155,128.4003801923077,139.73632384615385,{"y":151.0722675,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.705,8.234390942307693,12.763781884615385,17.293172826923076,21.82256376923077,26.35195471153846,30.881345653846154,35.410736596153846,39.94012753846154,44.46951848076923,48.998909423076924,53.52830036538462,58.05769130769231,{"y":62.58708225,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.705,4.748107846153847,5.791215692307693,6.834323538461539,7.877431384615385,8.920539230769233,9.963647076923078,11.006754923076924,12.04986276923077,13.092970615384617,14.136078461538464,15.17918630769231,16.222294153846157,{"y":17.265402,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.25,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.85,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.1,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.55,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.75,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.3,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.01,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.94,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.705,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€151.07Average Price Target€62.59Lowest Price Target€17.27
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:5WK0
H.C. Wainwright
H.C. Wainwright
€43.16
Buy
1133.24%
Upside
Reiterated
08/10/26
Analysts Offer Insights on Healthcare Companies: Aligos Therapeutics (NASDAQ: ALGS), aTyr Pharma (NASDAQ: ATYR) and Prime Medicine, Inc. (NASDAQ: PRME)
Piper Sandler Analyst forecast on DE:5WK0
Piper Sandler
Piper Sandler
€151.07
Buy
4216.35%
Upside
Reiterated
08/07/26
Piper Sandler Sticks to Their Buy Rating for Aligos Therapeutics (ALGS)
Lake Street Analyst forecast on DE:5WK0
Lake Street
Lake Street
€38.85
Buy
1009.92%
Upside
Reiterated
08/07/26
Lake Street Keeps Their Buy Rating on Aligos Therapeutics (ALGS)
Cantor Fitzgerald Analyst forecast on DE:5WK0
Cantor Fitzgerald
Cantor Fitzgerald
€17.27
Buy
393.30%
Upside
Reiterated
08/06/26
Cantor Fitzgerald Reaffirms Their Buy Rating on Aligos Therapeutics (ALGS)
Jefferies Analyst forecast on DE:5WK0
Jefferies
Jefferies
€41.44
Buy
1083.91%
Upside
Initiated
03/19/26
Aligos Therapeutics assumed with a Buy at JefferiesAligos Therapeutics assumed with a Buy at Jefferies
UBS
€17.27
Buy
393.30%
Upside
Reiterated
03/05/26
Analysts Offer Insights on Healthcare Companies: Aligos Therapeutics (NASDAQ: ALGS) and Cresco Labs (Other OTC: CRLBF)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:5WK0
H.C. Wainwright
H.C. Wainwright
€43.16
Buy
1133.24%
Upside
Reiterated
08/10/26
Analysts Offer Insights on Healthcare Companies: Aligos Therapeutics (NASDAQ: ALGS), aTyr Pharma (NASDAQ: ATYR) and Prime Medicine, Inc. (NASDAQ: PRME)
Piper Sandler Analyst forecast on DE:5WK0
Piper Sandler
Piper Sandler
€151.07
Buy
4216.35%
Upside
Reiterated
08/07/26
Piper Sandler Sticks to Their Buy Rating for Aligos Therapeutics (ALGS)
Lake Street Analyst forecast on DE:5WK0
Lake Street
Lake Street
€38.85
Buy
1009.92%
Upside
Reiterated
08/07/26
Lake Street Keeps Their Buy Rating on Aligos Therapeutics (ALGS)
Cantor Fitzgerald Analyst forecast on DE:5WK0
Cantor Fitzgerald
Cantor Fitzgerald
€17.27
Buy
393.30%
Upside
Reiterated
08/06/26
Cantor Fitzgerald Reaffirms Their Buy Rating on Aligos Therapeutics (ALGS)
Jefferies Analyst forecast on DE:5WK0
Jefferies
Jefferies
€41.44
Buy
1083.91%
Upside
Initiated
03/19/26
Aligos Therapeutics assumed with a Buy at JefferiesAligos Therapeutics assumed with a Buy at Jefferies
UBS
€17.27
Buy
393.30%
Upside
Reiterated
03/05/26
Analysts Offer Insights on Healthcare Companies: Aligos Therapeutics (NASDAQ: ALGS) and Cresco Labs (Other OTC: CRLBF)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
IMRXImmuneering
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Aligos Therapeutics

3 Months
Patrick TrucchioH.C. Wainwright
Success Rate
4/12 ratings generated profit
33%
Average Return
-4.32%
Copying Patrick Trucchio's trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of -4.32% per trade.
1 Year
Patrick TrucchioH.C. Wainwright
Success Rate
4/12 ratings generated profit
33%
Average Return
-10.56%
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -10.56% per trade.
2 Years
Patrick TrucchioH.C. Wainwright
Success Rate
4/12 ratings generated profit
33%
Average Return
-10.56%
Copying Patrick Trucchio's trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -10.56% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

5WK0 Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
6
13
12
11
8
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
13
12
11
8
In the current month, 5WK0 has received 8 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 5WK0 average Analyst price target in the past 3 months is 62.59.
Each month's total comprises the sum of three months' worth of ratings.

5WK0 Financial Forecast

5WK0 Earnings Forecast

The previous quarter’s earnings for 5WK0 were -€0.12.
The previous quarter’s earnings for 5WK0 were -€0.12.

5WK0 Sales Forecast

The previous quarter’s earnings for 5WK0 were €24.04M.
The previous quarter’s earnings for 5WK0 were €24.04M.

5WK0 Stock Forecast FAQ

What is DE:5WK0’s average 12-month price target, according to analysts?
Based on analyst ratings, Aligos Therapeutics’s 12-month average price target is 62.59.
    What is DE:5WK0’s upside potential, based on the analysts’ average price target?
    Aligos Therapeutics has 1688.20% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Aligos Therapeutics a Buy, Sell or Hold?
          Aligos Therapeutics has a consensus rating of Strong Buy, which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Aligos Therapeutics’s share price target?
            The average share price target for Aligos Therapeutics is 62.59. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €151.07 ,and the lowest forecast is €17.27. The average share price target represents 1688.20% Increase from the current price of €3.5.
              What do analysts say about Aligos Therapeutics?
              Aligos Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
                How can I buy shares of Aligos Therapeutics?
                To buy shares of DE:5WK0, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.